Pharmaceuticals

Enveric Biosciences

Enveric Biosciences released FY2025 9 Months earnings on November 14 (EST), actual revenue USD 0, actual EPS USD -37.0437

Enveric Biosciences released FY2025 Q3 earnings on November 14 (EST), actual revenue USD 0, actual EPS USD -10.8099

Enveric Completes Key CMC Milestones for EB-003, Paving the Way for Clinical Trials

Enveric Biosciences released FY2025 Semi-Annual Earnings on August 14 (EST), Actual Revenue: USD 0, Actual EPS: USD -25.7634

Enveric Biosciences released FY2025 Q2 earnings on August 14 (EST), actual revenue USD 0, actual EPS USD -0.9705 (forecast EPS USD -5.25)

Enveric Biosciences Inc. Announces Positive Preclinical Results for PTSD Drug EB-003

Enveric Announces New Data on EB-003 and Advances Development

Enveric Biosciences Receives Patent for Novel Neuroplastic Compound

Enveric Biosciences Obtains Patent for Sleep and CNS Disorders

Enveric Announces Positive Preclinical Results for Depression Drug Candidate EB-003

Enveric Submits Patent Application for Neurodegenerative Disease Treatment

Enveric Biosciences released FY2025 Q1 earnings on May 14 EST, actual revenue USD 0 (forecast USD --), actual EPS USD -14.5845 (forecast USD -71.9999)

Enveric Biosciences Obtains Patent for Addiction and Neuropsychiatric Disorders

Enveric Biosciences released FY2024 Annual Earnings on March 28 (EST), Actual Revenue: USD 0 (Forecast: USD 0), Actual EPS: USD -228.4763 (Forecast: USD -13.92)

Enveric Biosciences released FY2024 Q4 earnings on March 28 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -57.5896 (forecast USD -2.76)

Enveric Biosciences Inc expects a loss of 23 cents per share, with an analyst rating of Buy

Enveric Biosciences Plans to Seek Licensing or Sale of PsyAI™ Trademark Portfolio

Enveric Biosciences CEO Joseph Tucker Outlines Strategic Focus on EB-003 to Shareholders

Enveric Biosciences Obtains US Patent for EVM401 Series Non-Psychedelic Mekslin Derivatives

Enveric Biosciences, Inc. Announces Public Offering of 1,666,666 Shares to Raise Approximately $5 Million

A SPAC III Acquisition

PicoCELA

ECD Automotive Design

Davis Commodities

Universe Pharmaceuticals

Functional Brands

Starfighters Space

A SPAC III ACQUISITION CORP. COM NPV CL A (SUBS/RTS)02/01/2026

Paranovus ENT Tech

Can-Fite BioPharma

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap